Gemcitabine plus nab‐paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans
Keith Sigel(Icahn School of Medicine at Mount Sinai), Susan E. Bates(The Nature Conservancy), Tinaye Mutetwa(Icahn School of Medicine at Mount Sinai), Thierry Conroy(Inserm), Celine Yeh(Memorial Sloan Kettering Cancer Center), Paz Polak(Broad Institute), Juan P. Wisnivesky(General Department of Preventive Medicine), Girish N. Nadkarni(Icahn School of Medicine at Mount Sinai), Carlie Sigel(Memorial Sloan Kettering Cancer Center), Yeun‐Hee Anna Park(James J. Peters VA Medical Center), Béata Juzyna(UniCancer Group), Mengxi Zhou(Guangdong Provincial Center for Disease Control and Prevention), Mark Ychou(Institut de Recherche en Cancérologie de Montpellier), Tito Fojo(James J. Peters VA Medical Center)
Cited by 9
Related Papers
The repertoire of mutational signatures in human cancer
|Nature|2020|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k